Chikungunya vaccine candidate receives FDA Fast Track Designation

In a follow-up on Valneva's Chikungunya vaccine candidate, the France based biotech company announced Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VLA1553. VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate for protection against chikungunya. Wolfgang Bender, MD, PhD, chief medical officer of Valneva, commented, "Chikungunya is a growing ["]

The post Chikungunya vaccine candidate receives FDA Fast Track Designation appeared first on Outbreak News Today.